Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Q3 2026 Earnings Presentation
21 slides from Immunovia Ab's earnings presentation, Nov 2, 2026
Slide 1: Thank you for joining us. The webcast will start in a few minutes.
Thank you for joining us. The webcast will start in a few minutes. Q&A SESSION AND MATERIAL FORWARD-LOOKING STATEMENTS • Questions can be raised via the chat IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Comp
Slide 2: Immunovia Q3 2026 interim report
Immunovia Q3 2026 interim report
Slide 3: Agenda
Agenda • PancreaSure trial and adoption • Reimbursement and clinical studies • Business development • Q3 financial results • Rights issue • Q&A 3
Slide 4: We are pursuing clear focus areas to grow the business and create shareholder value
We are pursuing clear focus areas to grow the business and create shareholder value Commercial: Clinical Studies Partnerships & PancreaSure & Business Trial & Reimbursement Development Adoption 4
Slide 5: PancreaSure Trial & Adoption Q3 2026
PANCREASURE TRIAL & ADOPTION Q3 2026
Slide 6: Q3 marked our transition from the targeted advocacy stage to the volume building phase
Q3 marked our transition from the targeted advocacy stage to the volume building phase of the PancreaSure launch Phase TARGETED ADVOCACY VOLUME BUILDING REVENUE GROWTH Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27 Q3 27 Physician GI Groups, Pancreatologists KOLs & HRSCs Gastroenterologists & Other
Slide 7: 36 U.S. high-risk surveillance programs have used the PancreaSure test since launch
36 U.S. high-risk surveillance programs have used the PancreaSure test since launch Number of high-risk surveillance centers that have used PancreaSure 40 36 30 27 20 21 10 12 0 Q4 2025 Q1 2026 Q2 2026 Q3 2026 7
Slide 8: 12 of 36 high-risk clinics have reached the adoption stage as of Sep 30
12 of 36 high-risk clinics have reached the adoption stage as of Sep 30 ORDERING LATE-STAGE EARLY FULL REGISTERED TRIAL PROSPECTS ADOPTION ADOPTION Clinic has confirmed Had one or more they want to conversations; Clinic has ordered implement Clinic has placed 1-3 Clinic has ordered interested in tha
Slide 9: In Q3 we began targeting large gastroenterology practice groups
In Q3 we began targeting large gastroenterology practice groups • Saratoga Schenectady Gastroenterology Associates is our first gastroenterology group pilot • SSGA serves patients in rural New York state, far from high-risk surveillance programs in the city • After a successful trial with a lead gas
Slide 10: Reimbursement & Clinical Studies
REIMBURSEMENT & CLINICAL STUDIES
Slide 11: We continue to pursue multiple pathways to secure payment for PancreaSure tests
We continue to pursue multiple pathways to secure payment for PancreaSure tests 1 2 3 Insurance Payments Insurance Payments Payments from Patients Prior to Coverage After Coverage Timing Began Sep 2025 Began Feb 2026 2027 and beyond Expected average Medicare: $897 (8,350 SEK) $204 (2,005 SEK) To be
Slide 12: We achieved a major milestone with the submission of our Medicare coverage submission
We achieved a major milestone with the submission of our Medicare coverage submission • Medicare is the U.S. government health insurance for those over age 65+ • We submitted our application for coverage to MolDX on September 28 • The timeline of the review process is at the discretion of the MolDX
Slide 13: Near-term surveys and retrospective studies that support our reimbursement efforts are progressing well
Near-term surveys and retrospective studies that support our reimbursement efforts are progressing well Study Methodology and Objective Collaborators Status Data collection complete, analysis Physician survey of how PancreaSure DECIDE underway. Expect to announce changes clinical management of patie
Slide 14: Business Development Opportunities
BUSINESS DEVELOPMENT OPPORTUNITIES
Slide 15: Response to our business development outreach is very encouraging
Response to our business development outreach is very encouraging TARGET STATUS • Targets impressed by our commercial traction and our consistent of achievement U.S. Commercialization Partners of key milestones • Will share our commercial reimbursement results in Q4 • Exploring a promising licensing
Slide 16: Q3 2026 Financial Results & Rights Issue
Q3 2026 FINANCIAL RESULTS & RIGHTS ISSUE
Slide 17: Q3 Financial Results
Q3 Financial Results • Net sales increased to 843 KSEK (101) in the third quarter – and increased to 1 598 KSEK (330) in the first 9 months 2026. • Operating loss was 17,7 MSEK (25,1) in the third quarter – and the operating loss was 58,9 MSEK (64,0) in the first 9 months 2026. • Losses for the thir
Slide 18: Rights issue
Rights issue • We are conducting a rights issue of units that may provide the Company with approximately SEK 63,4 million before deduction of issue costs and fees to guarantors. • 80% of the rights issue is secured through subscription commitments from management and the Board of Directors, who have
Slide 19: We are raising capital through a rights issue to support our growth and achieve key milestones
We are raising capital through a rights issue to support our growth and achieve key milestones COMMERCIAL CLINICAL OPERATIONS Targeted Clinical studies to General company investment in show the patient expenses such as sales and benefits of using the cost to marketing to PancreaSure to operate our U
Slide 20: Rights issue proceeds will fund robust clinical studies to generate data supporting payer coverage decisions
Rights issue proceeds will fund robust clinical studies to generate data supporting payer coverage decisions and reimbursement STUDY OBJECTIVES METHODOLOGY COLLABORATORS Assess PancreaSure sensitivity and specificity in Prospective controlled NIH Cyst Study detecting cancer in cyst patients trial As
Slide 21: investors.immunovia.com
To learn more about the rights issue, please visit investors.immunovia.com